Recently,Shanghai Yuanbao Medical Device Co., Ltd. (referred to as "Yuanbao Medical") announced the completion of an angel round of financing worth tens of millions of yuan, exclusively strategically invested by the Intellectual Property Fund under Shanghai Science and Technology Investment Group.It is reported that the funds raised will be mainly used for the research and development iteration, clinical registration application, benchmark market expansion, and continuous innovation of cutting-edge technologies for two core products: the intelligent precision neural circuit multi-target regulation robotic system and the MRI-targeted computing AI system. This will inject new momentum into the company’s development in the intersection field of brain-computer interfaces and neurorehabilitation.
Notably, the exclusive investor this time — the Intellectual Property Fund, established on September 18, 2016 — is the first mixed-ownership reform demonstration fund of Shanghai Science and Technology Innovation Group, as well as a key component of the group's "1+3" fund system. Shanghai Science and Technology Innovation Group, a subsidiary of Shanghai State Investment (Group), was founded in 1992 and is one of the earliest science and technology investment institutions established in China. After its integration, it further strengthened the synergy between state-owned capital and market-oriented mechanisms.
The Intellectual Property Fund has been focusing on the key layout of Shanghai's "3+6" new industrial system for a long time, adhering to the strategy of investing early, small, in hard technology, and core intellectual property. The fields of neuromodulation, brain-computer interfaces, and high-end rehabilitation devices have broad clinical needs and significant space for localization in China, making them core strategic directions in the life and health sector. This investment in Yuanbao Medical may well be another crucial move by the Intellectual Property Fund in this field.
Since its establishment in 2022, Yuanbao Medical has been deeply engaged in the interdisciplinary fields of brain science, intelligent neuromodulation, and neurorehabilitation, committed to building a full-chain innovation system from basic research to industrial implementation.
The company's core team consists of top experts in the fields of brain science, neurorehabilitation, medical imaging, artificial intelligence, medical robotics, and clinical medicine. Relying on the Precision Neural Circuit Multi-Target Modulation Joint Laboratory co-built with the Intelligent Rehabilitation Engineering Center of the Ministry of Education at Shanghai University of Traditional Chinese Medicine, as well as the core force control fitting algorithm jointly developed with the Intelligent Robotics Research Center of Zhejiang University, the company has achieved a critical leap from core technology breakthroughs to product implementation, establishing an independently controlled technical barrier.
The company builds its core competitiveness in hardcore technology based on the principles of brain networks.
At the theoretical levelThe company has broken through the technical limitations of traditional single-target and local brain region stimulation, and innovatively proposed a "symptom-circuit mapping"-guided transcranial magnetic stimulation treatment theory. This approach takes neural circuits as the core unit of disease intervention, achieving a conceptual innovation from "local brain region intervention" to "whole-brain network regulation."
At the technical levelThe company has built a multi-modal fusion neural circuit decoding system integrating EEG signals and functional structural imaging, established voxel-level individualized neural circuit mapping technology, and pioneered the integration of synaptic plasticity learning rules into non-invasive neuromodulation. It has innovatively developed paired associative stimulation technology, breaking through industry bottlenecks in the modulation of deep brain nuclei and long-range neural circuits, forming a full-dimensional "point-line-surface" intelligent neuromodulation system encompassing the cortex, subcortex, and neural circuits.
At the clinical translation levelThe company has independently developed customized intelligent regulation paradigms for diseases such as amnestic mild cognitive impairment and motor dysfunction after stroke. The efficacy has been verified through multi-center, double-blind, randomized controlled clinical studies, achieving a complete transformation from mechanistic innovation to clinical benefits.
Relying on the core capabilities of full-information decoding of EEG-imaging neural circuits and intelligent neuromodulation, the company has taken the lead in entering the Neuromodulation 2.0 era — from single cortical stimulation to long-term circuit regulation, from fixed targets to individualized precision targeting, and from passive intervention to a closed-loop system of non-invasive brain-computer interfaces.
At present, the company's two core products:
Intelligent Precision Neural Circuit Multi-Target Regulation Robotic System: Achieves precise positioning and stable intervention in neural regulation through multi-modal visual positioning, AI analysis of medical imaging, and intelligent coordination with robotic arms.
AI System for Magnetic Resonance Imaging Target Calculation: Based on high-precision post-processing of full-modal brain imaging and artificial intelligence models, providing underlying algorithm support for closed-loop brain-computer interfaces, intelligent neuromodulation, and traditional Chinese medicine-brain collaboration.
In addition, Yuanbao Medical stated that it will actively explore cutting-edge fields such as non-invasive brain-computer interfaces, the integration of traditional Chinese medicine with brain-computer technology, and closed-loop intelligent neuromodulation, serving as a bridge connecting advanced brain science research with clinical applications. The goal is to create a leading brain disease rehabilitation and brain-computer interface innovation platform in China that is internationally competitive.
